Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

8,563 total articles

ADP: The Panic Pullback Built a Risk-Reward Edge — Buy on Weakness

ADP: The Panic Pullback Built a Risk-Reward Edge — Buy on Weakness

Automatic Data Processing (ADP) has been punished during the AI selloff and a soft labor narrative, pushing the stock near its 2026 lows. Fundamentals - $5.29B free cash flow, $1.70 quarterly dividend, and earnings of $10.87 per share - still support a mid-to-long-term rebound. This trade idea lays out an entry at $224.525, a protective stop at $20…

Microsoft: If AI Is Real, Hyperscalers Are Mispriced - Buy the Dip

Microsoft: If AI Is Real, Hyperscalers Are Mispriced - Buy the Dip

Microsoft ($MSFT) is trading at $373.10 with a $2.77 trillion market cap, P/E ~22 and free cash flow of ~$72.9B. If generative AI drives sustained revenue and margin expansion for Azure and Copilot, Microsoft’s current multiples understate the company’s optionality. This trade idea buys the recent weakness with a clear stop and a target that prices…

Galaxy Digital: 4 Near-Term Catalysts That Could Drive a 25%+ Rally

Galaxy Digital: 4 Near-Term Catalysts That Could Drive a 25%+ Rally

Galaxy Digital (GLXY) offers asymmetric upside if crypto markets and tokenization adoption re-accelerate. Market cap sits at $11.08B and the stock trades near $28.41 after a bruising 2025. We lay out four catalysts that can push the shares higher, an actionable entry/stop/target plan for a mid-term swing, and the key risks that could derail the the…

MeiraGTx: Betting on a Manufacturing-Driven Re-Rating

MeiraGTx: Betting on a Manufacturing-Driven Re-Rating

MeiraGTx has quietly assembled the commercial building blocks that could turn gene-therapy R&D into recurring revenue: a newly reacquired ophthalmology asset with Phase 3 data, a strategic collaboration with Eli Lilly, and retained manufacturing capability. With the stock trading near a 52-week high at a market cap of roughly $1.12B, we think the m…

Apogee Enterprises: A Defensive Long for AI-Heavy Portfolios

Apogee Enterprises: A Defensive Long for AI-Heavy Portfolios

Apogee Enterprises (APOG) is a quietly profitable building-products operator that offers diversified revenue streams, steady free cash flow, and a 2%+ yield. For investors looking to hedge concentrated AI or tech bets, APOG provides non-tech cyclical exposure with an attractive FCF yield and near-term catalysts tied to margin programs and recent ac…

TORM Back on Sale: Buy Ahead of Q2 — Dividend and Fundamentals Offer a Comfortable Rebound Trade (Upgrade)

TORM Back on Sale: Buy Ahead of Q2 — Dividend and Fundamentals Offer a Comfortable Rebound Trade (Upgrade)

TORM (TRMD) is trading well below where its fundamentals and recent results justify. A history of beats and raised guidance, a 9%+ dividend yield and attractive valuation (PE 7.7, PB 1.2) argue for a rebound if Q2 results come in line or better. This trade targets a mid-term recovery into the $30s, with a defined entry, stop and target that balance…